Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Circulation Journal

• Publication date

  2018-04-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/circj.CJ-17-1318PMID 29553090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of long‐term net clinical outcomes using the TIMI‐AF score: Comparison with CHA2DS2‐VASc and HAS‐BLED

  2018cited by this paper
• Practice guidelines for themanagement of arterial hypertension of the European Society of Hypertension ( ESH ) and the European Society of Cardiology ( ESC ) ESH / ESCTask Force for theManagement of Arterial Hypertension

  2018cited by this paper
• Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.

  2017cited by this paper
• A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial

  2017cited by this paper
• The ABC pathway: an integrated approach to improve AF management

  2017cited by this paper
• Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.

  2017cited by this paper
• Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study

  2017cited by this paper
• Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.

  2017cited by this paper
• Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms

  2016cited by this paper
• Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation.

  2016cited by this paper
• Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score

  2016cited by this paper
• Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.

  2016cited by this paper
• Causes of Death in Anticoagulated Patients With Atrial Fibrillation.

  2016cited by this paper
• Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.

  2015cited by this paper
• Atrial fibrillation and the risk of myocardial infarction.

  2015cited by this paper
• Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

  2014cited by this paper
• Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation

  2014cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Bleeding risk assessment and management in atrial fibrillation patients

  2011cited by this paper
• Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

  2010cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Stroke Associated with Atrial Fibrillation – Incidence and Early Outcomes in the North Dublin Population Stroke Study

  2009cited by this paper
• Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.

  2008cited by this paper
• Bmc Medical Informatics and Decision Making Extensions to Decision Curve Analysis, a Novel Method for Evaluating Diagnostic Tests, Prediction Models and Molecular Markers

  2008cited by this paper
• Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data

  2008cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Decision Curve Analysis: A Novel Method for Evaluating Prediction Models

  2006cited by this paper
• Stroke severity in atrial fibrillation. The Framingham Study.

  1996cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper

• Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

  2022cites this paper
• Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation.

  2020cites this paper
• Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach

  2019cites this paper
• OP-EUPA180177 1..27

  2018influential citation
• 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European

  2018influential citation